Detailed description page of THPdb

This page displays user query in tabular form.

Th1149 details

Primary information
ID 1653
ThPP ID Th1149
Therapeutic Peptide/Protein Name Ragweed Pollen Extract
Sequence N.A. view full sequnce in fasta
Functional Classification IIIa
Molecular Weight N.A.
Chemical Formula N.A.
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description Ragweed pollen extract has been developed by Curalogic. The company has initiated a phaseÂ IIIÂ trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
Indication/Disease Investigated for use/treatment in allergic reaction.
Pharmacodynamics Precise mechanism of allergen immunotherapy is not known
Mechanism of Action Ragweed pollen extract is the oral immunotherapy delivered via microencapsulated beads put into a capsule, which enables the antigen to be delivered more efficiently to the Peyer's patches in the jejunum and duodenum, where the antigen can be presented and processed and not destroyed by stomach acid.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Ragwitek
Company Merck Sharp & Dohme
Brand Discription Ragwitek tablets contain pollen allergen extract from Short Ragweed (Ambrosia artemisiifolia). It is a sublingual orally disintegrating tablet that dissolves rapidly. It is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract.
Prescribed for Ragwitek is anÂ allergenÂ extract indicated asÂ immunotherapyÂ for the treatment of shortÂ ragweedÂ pollen-induced allergicÂ rhinitis, with or withoutconjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specificÂ IgEÂ antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance Tablets
Route of Administration Oral route
Recommended Dosage One ragwitek tablet daily.
Contraindication Ragwitek is contraindicated in patients with severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction after taking any sublingual allergen immunotherapy, history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product.
Side Effects Throat irritation, oralpruritus, ear pruritus, oralÂ paraesthesia, mouth edema, and tongue pruritus.
Useful Link http://www.rxlist.com/ragwitek-drug/indications-dosage.htm
PubMed ID 12811019, 8760779
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1653
ThPP ID	Th1149
Therapeutic Peptide/Protein Name	Ragweed Pollen Extract
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIIa
Molecular Weight	N.A.
Chemical Formula	N.A.
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Ragweed pollen extract has been developed by Curalogic. The company has initiated a phaseÂ IIIÂ trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
Indication/Disease	Investigated for use/treatment in allergic reaction.
Pharmacodynamics	Precise mechanism of allergen immunotherapy is not known
Mechanism of Action	Ragweed pollen extract is the oral immunotherapy delivered via microencapsulated beads put into a capsule, which enables the antigen to be delivered more efficiently to the Peyer's patches in the jejunum and duodenum, where the antigen can be presented and processed and not destroyed by stomach acid.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Ragwitek
Company	Merck Sharp & Dohme
Brand Discription	Ragwitek tablets contain pollen allergen extract from Short Ragweed (Ambrosia artemisiifolia). It is a sublingual orally disintegrating tablet that dissolves rapidly. It is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract.
Prescribed for	Ragwitek is anÂ allergenÂ extract indicated asÂ immunotherapyÂ for the treatment of shortÂ ragweedÂ pollen-induced allergicÂ rhinitis, with or withoutconjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specificÂ IgEÂ antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	Tablets
Route of Administration	Oral route
Recommended Dosage	One ragwitek tablet daily.
Contraindication	Ragwitek is contraindicated in patients with severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction after taking any sublingual allergen immunotherapy, history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product.
Side Effects	Throat irritation, oralpruritus, ear pruritus, oralÂ paraesthesia, mouth edema, and tongue pruritus.
Useful Link	http://www.rxlist.com/ragwitek-drug/indications-dosage.htm
PubMed ID	12811019, 8760779
3-D Structure	N.A.

Updated version of this database is available at ThpDB2

Detailed description page of THPdb